California Endowment Oakland Conference Center
2000 Franklin St.
Oakland, CA, 94612
2345 Commonwealth Avenue
Newton, MA 02466
The Midwest CEPAC will convene to deliberate on ICER's report on voretigene neparvovec.
The California Technology Assessment Forum will convene to discuss evidence on CAR-T therapies.
The New England CEPAC will convene to review the comparative clinical effectiveness and value of emicizumab for treatment of hemophilia A.
The Midwest CEPAC convened to discuss the findings of ICER's report on the comparative clinical effectiveness and value of treatment for ovarian cancer.
ICER will develop a report reviewing the clinical effectiveness and value of abuse-deterrent opioids. The report will be the subject of a July 20, 2017 meeting of the New England CEPAC.
The CTAF Panel will convene to review ICER's report on drug treatments for osteoporosis.
ICER hosted a multi-stakeholder policy summit to discuss methods for assessing the value of new drugs for rare conditions. The summit included discussion of how methods can be applied to recommend fair prices that reflect the value of orphan drugs to patients and the health system, to allow for broader insurance coverage for innovative new treatments.
The Midwest CEPAC convened in May 2017 to discuss ICER's report on dupilumab and crisaborole for atopic dermatitis.
The New England CEPAC convened on March 24, 2017 to discuss ICER's report on treatments for rheumatoid arthritis.
The California Technology Assessment Forum convened to discuss ICER's report on treatments for Multiple Sclerosis.
The New England CEPAC convened to deliberate and vote on evidence presented in ICER's report on treatments for psoriasis.
The Midwest CEPAC convened in October 2016 to discuss ICER's report on treatments for non-small cell lung cancer.
The New England CEPAC convened to deliberate and vote on evidence presented in ICER's report on obeticholic acid (Intercept Pharmaceuticals, Inc.) for use in PBC and NASH.